TKI De-escalation Safe in Most CML Patients With Major Molecular Response

A de-escalation of tyrosine-kinase inhibitor dose was safe in the majority of patients with chronic myeloid leukemia with stable major molecular response.
Source: CancerNetwork - Category: Cancer & Oncology Tags: Chronic Myeloid Leukemia News Source Type: news